ArticleBritish journal of haematology2017
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Article in British journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 71 citations in OpenAlex.
- A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.Leukemia & lymphoma · 2022Trial
- Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Trial
- Primary refractory disease in large B-cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial.Blood advances · 2026Article
- Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study.The oncologist · 2025Observational
- Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk.Annals of hematology · 2025Review
- Patients With Relapsed Large B-Cell Lymphoma After 12 Months Have a Similarly Poor Prognosis to Those Relapsing Within 12 Months.European journal of haematology · 2025Article
- Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis.Blood neoplasia · 2025Article
- Article
- Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma.Therapeutic advances in medical oncology · 2025Article
- Article
- Clinical outcomes of patients with newly diagnosed large B-cell lymphoma in a safety-net hospital system.Blood neoplasia · 2024Article
- Defining primary refractory large B-cell lymphoma.Blood advances · 2024Article
- Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.Haematologica · 2024Article
- [Chinese expert consensus on the diagnosis and management of elderly patients with diffuse large B-cell lymphoma (2024)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.Advances in therapy · 2024Article
- Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin's lymphoma.Exploration of targeted anti-tumor therapy · 2024Review
- Early failure is still a poor prognostic factor in patients with relapsed or refractory large B-cell lymphoma in the era of CAR T-cell therapy.Journal of clinical and experimental hematopathology : JCEH · 2024Article
- CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.Oncoimmunology · 2024Article
- Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma.Hematological oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
Abstract
This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse. Patients with relapse on follow-up and subsequently retreated were included in this analysis. 1039 patients received anthracycline-based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years (OS4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (autoHCT) with OS4 from autoHCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS4 of 47% but those with a transient or no response to initial therapy had OS4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo autoHCT. The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.